Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state medicaid program: A retrospective, cross-sectional, descriptive, database analysis

Clinical Therapeutics

Volumn 29, Issue 11, 2007, Pages 2456-2467

  Khanna, Rahul ^a   Smith, Michael J ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

costs; Medicaid; medical services use; prescription medication use; rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID;

ADOLESCENT; ADULT; ARTICLE; BILLING AND CLAIMS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DATA BASE; DEMOGRAPHY; DESCRIPTIVE RESEARCH; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HEALTH SERVICE; HOSPITALIZATION; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL SERVICE; PRESCRIPTION; PREVALENCE; PROFESSIONAL PRACTICE; RACE DIFFERENCE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DRUG UTILIZATION; ETHNIC GROUPS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICAID; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; WEST VIRGINIA;

EID: 37349049597     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.11.009     Document Type: Article

References (40)

1. Feldmann M., Brennan F., and Maini R. Rheumatoid arthritis. Cell 85 (1996) 307-310
2. Lawrence R., Helmick C., Arnett F., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41 (1998) 778-799
3. Gabriel S., Crowson C., and O'Fallon W. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum 42 (1999) 415-420
4. Doran M., Pond G., Crowson C., et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 46 (2002) 625-631
5. Riise T., Jacobsen B., and Gran J. Incidence and prevalence of rheumatoid arthritis in the county of Troms, northern Norway. J Rheumatol 27 (2000) 1386-1389
6. Zwerina J., Redlich K., Schett G., and Smolen J. Pathogenesis of rheumatoid arthritis: Targeting cytokines. Ann N Y Acad Sci 1051 (2005) 716-729
7. Bengtsson C., Nordmark B., Klareskog L., et al., EIRA Study Group. Socioeconomic status and the risk of developing rheumatoid arthritis: Results from the Swedish EIRA study. Ann Rheum Dis 64 (2005) 1588-1594
8. Griffith J., and Carr A. What is the impact of early rheumatoid arthritis on the individual?. Best Pract Res Clin Rheumatol. 15 (2001) 77-90
9. Pugner K., Scott D., Holmes J., and Hieke K. The costs of rheumatoid arthritis: An international long-term view. Semin Arthritis Rheum 29 (2000) 305-320
10. Wolfe F., and Hawley D. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients. J Rheumatol 25 (1998) 2108-2117
11. US Dept of Health and Human Services. With understanding and improving health and objectives for improving health. Healthy People 2010 (2000), US Government Printing Office, Washington, DC
12. Kvien T., Uhlig T., Odegard S., and Heiberg M. Epidemiological aspects of rheumatoid arthritis: The sex ratio. Ann N Y Acad Sci 1069 (2006) 212-222
13. Hulsemann J., Mittendorf T., Merkesdal S., et al. Direct costs related to rheumatoid arthritis: The patient perspective. Ann Rheum Dis 64 (2005) 1456-1461
14. Griffiths R., Bar-Din M., MacLean C., et al. Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy. Arthritis Care Res 13 (2000) 213-226
15. Michaud K., Messer J., Choi H., and Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: A three-year study of 7,527 patients. Arthritis Rheum 48 (2003) 2750-2762
16. Jacobi C., Triemstra M., Rupp I., et al. Health care utilization among rheumatoid arthritis patients referred to a rheumatology center: Unequal needs, unequal care?. Arthritis Rheum. 45 (2001) 324-330
17. Birnbaum H., Barton M., Greenberg P., et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med 42 (2000) 588-596
18. Lanes S., Lanza L., Radensky P., et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: The importance of drug and surgery costs. Arthritis Rheum 40 (1997) 1475-1481
19. Yelin E., Criswell L., and Feigenbaum P. Health care utilization and out-comes among persons with rheumatoid arthritis in fee-for-service and prepaid group practice settings. JAMA 276 (1996) 1048-1053
20. Centers for Medicare and Medicaid Services (CMS). Medicaid information resource [CMS Web site] (July 30, 2006). http://www.cms.hhs.gov/home/medicaid.asp Accessed
21. National Center for Health Statistics. Classification of Diseases, Functioning, and Disability-What's New [Centers for Disease Control and Prevention Web site] (July 30, 2006). http://www.cdc.gov/nchs/icd9.htm Accessed
22. Ilowite N. Current treatment of juvenile rheumatoid arthritis. Pediatrics 109 (2002) 109-115
23. D'Hoore W., Bouckaert A., and Tilquin C. Practical considerations on the use of the Charlson Comorbidity Index with administrative data bases. J Clin Epidemiol 49 (1996) 1429-1433
24. Hospital inpatient procedures. Hospital inpatient DRG benchmark fees search [INTELLIMED International Corporation Web site] (May 30, 2006). http://www.myhealthscore.com/consumer/inpfeesearch.htm Accessed
25. Cunningham L., and Kelsey J. Epidemiology of musculoskeletal impairments and associated disability. Am J Public Health 74 (1984) 574-579
26. Aho K., Kaipiainen-Seppanen O., Heliovaara M., and Klaukka T. Epidemiology of rheumatoid arthritis in Finland. Semin Arthritis Rheum 27 (1998) 325-334
27. Hootman J., Helmick C., and Schappert S. Magnitude and characteristics of arthritis and other rheumatic conditions on ambulatory medical care visits, United States, 1997. Arthritis Rheum 47 (2002) 571-581
28. Kleinman J., Gold M., and Makuc D. Use of ambulatory medical care by the poor: Another look at equity. Med Care 19 (1981) 1011-1029
29. Ashton C., Haidet P., Paterniti D., et al. Racial and ethnic disparities in the use of health services: Bias, preferences, or poor communication?. J Gen Intern Med. 18 (2003) 146-152
30. Skoldstam L., Brudin L., Hagfors L., and Johansson G. Weight reduction is not a major reason for improvement in rheumatoid arthritis from lactovegetarian, vegan or Mediterranean diets. Nutr J 4 (2005) 15
31. van den Ende C., Breedveld F., le Cessie S., et al. Effect of intensive exercise on patients with active rheumatoid arthritis: A randomised clinical trial. Ann Rheum Dis 59 (2000) 615-621
32. Hakkinen A., Sokka T., Kotaniemi A., and Hannonen P. A randomized two-year study of the effects of dynamic strength training on muscle strength, disease activity, functional capacity, and bone mineral density in early rheumatoid arthritis. Arthritis Rheum 44 (2001) 515-522
33. Centers for Disease Control and Prevention (CDC). Behavioral risk factor surveillance system survey data (2005), CDC, Atlanta, Ga
34. Centers for Disease Control and Prevention (CDC). Adult participation in recommended levels of physical activity-United States, 2001 and 2003. MMWR Morb Mortal Wkly Rep 54 (2005) 1208-1212
35. Finkelstein E., Fiebelkorn I., and Wang G. State-level estimates of annual medical expenditures attributable to obesity. Obes Res 12 (2004) 18-24
36. Berard A., Solomon D., and Avorn J. Patterns of drug use in rheumatoid arthritis. J Rheumatol 27 (2000) 1648-1655
37. Friesen W., Hekster Y., van de Putte L., and Gribnau F. Cross-sectional study of rheumatoid arthritis treatment in a university hospital. Ann Rheum Dis 44 (1985) 372-378
38. Ward M., and Fries J. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. J Rkeumatol. 25 (1998) 408-416
39. Mottonen T., Hannonen P., Leirisalo-Repo M., et al., FIN-RACo Trial Group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. Lancet 353 (1999) 1568-1573
40. Klareskog L., van der Heijde D., de Jager J., et al., TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 363 (2004) 675-681